ALMS ALUMIS INC.
FY2024 10-K
ALUMIS INC. (ALMS) filed its fiscal year 2024 10-K annual report with the SEC on Mar 19, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2024 10-K
Business Overview
- • Core business: Clinical-stage biopharmaceutical developing precision TYK2 inhibition therapies for immune-mediated diseases
- • New emphasis: Initiated Phase 1 trial of CNS-penetrant TYK2 inhibitor A-005 targeting MS and neurodegenerative diseases, reporting initial results in Dec 2024
Management Discussion & Analysis
- • Revenue, profit, segment, cash flow, and guidance data not disclosed in provided text
Risk Factors
- • Regulatory risk: FDA current cGMP compliance reliance on CMOs for manufacturing, with no own facilities impacting supply chain control
- • Macroeconomic threat: ongoing Ukraine and Israel conflicts potentially disrupting operations and financing access amid global instability
Get deeper insights on ALUMIS INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.